CurrentPremera BluecrossPolicy 2.04.509

Cardiovascular Risk Panels

Defines coverage stance for laboratory panels that combine multiple biomarkers to assess cardiovascular disease (CVD) risk and informs providers when such panels are considered medically necessary or not for Premera Bluecross members.

Policy Summary

PayerPremera Bluecross

PolicyCardiovascular Risk Panels

Policy CodePolicy 2.04.509

Change TypeNo material change

Effective DateMar 1, 2026

Next Review Date

Key ActionIf components of testing are billed, submit appropriate individual CPT codes for each measured analyte.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessaryCoverage stance

No specific CPT codeCPT code availability

removed 81291Recent coding change

through Oct 28, 2025Literature update

Coverage Criteria

Not Medically Necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered when guideline-based selective use criteria are met

Guideline-based stance and selective use recommendations

ACC/AHA 2013 pooled cohort guidance: Use age- and sex-specific pooled cohort equations with total cholesterol and HDL for 10-year risk estimation in non-Hispanic black and non-Hispanic white adults 40–79; if risk-based treatment decision is uncertain, consider assessment of ≥1 of family history, hs-CRP, CAC score, or ABI to inform decision-making (Class IIb).age 40–79

ACC/AHA does not recommend other novel cardiac risk factors or panels of cardiac risk factors.

ESC/EAS lipid markers guidance: Recommend non-HDL-C and apolipoprotein B for risk assessment, especially in people with high triglycerides, diabetes, obesity, or very low LDL-C; lipoprotein(a) recommended at least once in adulthood and when family history of premature CVD or borderline risk classification (Class IIa).Lipoprotein(a) ≥180 mg/dL

ESC/EAS 2019 guideline and 2025 update reinforce these recommendations.

ESC 2021 prevention guidance: Routine collection of potential modifiers (genetic risk scores, circulating biomarkers, vascular tests other than CAC or carotid ultrasound) is not recommended.

2025 ESC statement does not advocate routine use of cardiovascular risk panels due to evidence gaps.

USPSTF 2018 position: USPSTF found insufficient evidence to determine whether adding ABI, hsCRP, or CAC score to traditional models improves outcomes and assigned an I grade for their use in routine risk assessment; did not endorse cardiovascular risk panels or nontraditional biomarkers for routine use.

Emphasizes need for outcome-based evidence before endorsing these tools for general screening.

Routine collection or routine use of broad multi-marker cardiovascular risk panels and many nontraditional biomarkers is not recommended for general clinical practice. The ESC guidance states that routine collection of potential modifiers such as genetic risk scores or circulating biomarkers is not recommended, and a 2025 ESC statement reiterated that guidelines do not currently advocate routine use of cardiovascular risk panels. The USPSTF similarly assigned an 'I' grade for several nontraditional markers (ABI, hsCRP, CAC) and did not endorse bundled multimarker panels for routine risk assessment. The ACC/AHA guidance limits additional testing to selective use (e.g., family history, hs-CRP, CAC, or ABI) when quantitative risk assessment leaves treatment decisions uncertain and does not recommend panels of cardiac risk factors.

Cardiovascular risk panels (commercial multimarker panels) are considered not medically necessary because current evidence does not demonstrate that their use improves clinical management or patient outcomes compared with conventional risk assessment. Systematic reviews and cohort studies primarily report predictive performance; randomized trials showing that panel use changes management or reduces events are limited or absent. Given the lack of outcome-based evidence, routine implementation of these commercial panels is unsupported.

Panels of novel cardiac risk factors and routine use of other novel cardiac biomarkers beyond a small set of selectively applied markers are not supported. Major guideline bodies (ACC/AHA, ESC/EAS, USPSTF) do not recommend routine bundled use of novel markers; instead, selective application of individual modifiers such as hs-CRP, CAC, ABI, lipoprotein(a), or apolipoprotein B may be considered in specific contexts. Broad multimarker commercial panels lack outcome-based validation and therefore are not recommended for routine clinical use.

Coding

Example component CPT/PLA codesmixed

82465	Cholesterol, serum or whole blood, total.
82652	Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed.
83090	Homocysteine.
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2).
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol).
83721	Lipoprotein, direct measurement; LDL cholesterol.
83722	Lipoprotein, direct measurement; small dense LDL cholesterol.
83880	Natriuretic peptide.
84478	Triglycerides.
86141	C-reactive protein; high sensitivity (hsCRP).

1–10 of 12

1/2

Policy coding notesCPT

81291

CPT code removed from this policy (reviewed by Carelon)

Provider Actions and Billing Guidance

Prior Authorization

Member Benefit Verification

Consult the member benefit booklet or contact Member Services to verify plan coverage, benefit limits, and prior authorization requirements before ordering testing.

Verify whether prior authorization is required for individual component tests or panel services.
If member benefits exclude panels of biomarkers, order and bill individual component CPT codes where appropriate (see Coding).

Denial Risk

Denial Risk for Cardiovascular Risk Panels / Billing Components

Claims for multimarker cardiovascular risk panels (panels that combine multiple biomarkers beyond a simple lipid panel) are considered not medically necessary and may be denied. Submit individual CPT codes for each measured analyte when medically appropriate and supported by documentation.

Cardiovascular risk panels listed as examples (e.g., Atherotech CVD Risk Panel, Boston Heart Cardiovascular Map, Quest Cardio IQ, Cleveland HeartLab panels, Ceramides panels) are considered not medically necessary.
Bill components using standard CPT codes for each analyte when testing of specific biomarkers is clinically indicated.

Billing Rule

Coding and Prior Authorization Note

There is no unique CPT for cardiovascular risk panels. Submit the individual component CPT codes for each measured analyte. Verify prior authorization requirements with the payer for any remaining codes.

Submit individual CPT codes for each measured analyte (examples in Coding section).
CPT 81291 has been removed from this policy — verify if prior auth is required for remaining codes.

Step Therapy

No step therapy provisions specified for cardiovascular risk panels in this policy.

Denial Risk

Denial Risk for Nonconforming Requests

Services that do not meet the criteria in this policy may be denied as not medically necessary.

When ordering, ensure documentation supports medical necessity for each individual component test to reduce risk of denial.

Background

Cardiovascular risk panels combine multiple biomarkers — for example, traditional lipid measures plus inflammatory markers, metabolic parameters, and genetic variants — into a single assessment intended to estimate future cardiovascular disease risk. These panels go beyond a simple lipid panel (total cholesterol, LDL, HDL, triglycerides) and may include calculated ratios or additional analytes; however, evidence to show that multi-marker panels improve decision-making or clinical outcomes compared with conventional risk scores and selective risk modifiers is insufficient.

Definitions

inv-18: Cardiovascular risk panels — definition and examples of included biomarkers

DefinitionCombinations of multiple individual biomarkers intended to assess cardiac risk beyond a simple lipid panel, including lipids, inflammatory markers, metabolic parameters, and genetic markers.

PurposeReport results of multiple individual tests to estimate cardiovascular disease (CVD) risk; distinct from quantitative risk scores that combine markers into a single score.

Examples (commercial panels)Atherotech VAP and CVD Risk Panel; Boston Heart Cardiovascular Map Panels; CardioVIP/Spectracell Metabolic Characterization; CV Health Plus (Genova); Cleveland Heart Lab CVD Inflammatory Profile; MI-HEART Ceramides Panel (Mayo Clinic); Quest Cardio IQ and Advanced Heart Health Test Panel; Singulex SMC assays; Veridia SMC cardiac function.

Scope exclusionThis policy does not address use of biomarker panels for diagnosis of acute myocardial infarction.

inv-19: Simple lipid panel — typical components

Typical componentsTotal cholesterol; low-density lipoprotein (LDL) cholesterol; high-density lipoprotein (HDL) cholesterol; triglycerides.

Additional reportsCalculated ratios such as total/HDL cholesterol may also be reported as part of a simple lipid panel.

DistinctionOther lipid tests (apolipoproteins, lipoprotein particle number/size, lipoprotein(a), etc.) are not considered part of a simple lipid panel for the purposes of this policy.

inv-20: Quantitative risk assessment — pooled cohort equations and use

DefinitionUse of age- and sex-specific pooled cohort equations including total cholesterol and HDL to predict 10-year risk of a first hard atherosclerotic cardiovascular disease event.

PopulationRecommended for non-Hispanic black and non-Hispanic white adults aged 40–79 years.

When to consider additional markersIf treatment decision remains uncertain after quantitative risk assessment, consider ≥1 of: family history, hs-CRP, coronary artery calcium (CAC) score, or ankle-brachial index (ABI) to inform decision-making (Class IIb).

inv-21: Non-HDL-C / Apolipoprotein B — lipid-related measurements recommended by ESC/EAS

Recommended measurementsNon–HDL cholesterol and apolipoprotein B are recommended for risk assessment, particularly in people with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL-C.

Role of ApoBApolipoprotein B can be used as an alternative to LDL-C for screening, diagnosis, and management, and may be preferred over non–HDL-C in certain high-triglyceride or metabolic conditions.

Evidence levelESC/EAS gives Class I recommendation with Level C evidence for non–HDL-C and apolipoprotein B in these contexts.

inv-22: Lipoprotein(a) — recommendation and threshold context

RecommendationMeasure lipoprotein(a) at least once in adulthood to identify individuals with inherited levels associated with high lifetime cardiovascular risk.

Threshold contextESC/EAS identifies levels exceeding 180 mg/dL as conferring risk comparable to heterozygous familial hypercholesterolemia.

When else to measureAlso advised when there is a family history of premature cardiovascular disease or when risk classification is borderline between moderate and high (Class IIa).